Leukemia Research
Volume 25, Issue 9 , Pages 793-800 , 1 September 2001

Effects of Matrine on proliferation and differentiation in K-562 cells

  • L.P Zhang

      Affiliations

    • Chongqing University of Medical Science, Chongqing 400046, People's Republic of China
    • Corresponding Author InformationCorresponding author
    • ,
  • J.K Jiang

      Affiliations

    • Chongqing University of Medical Science, Chongqing 400046, People's Republic of China
    • ,
  • J.W.O Tam

      Affiliations

    • Department of Biochemistry, Faculty of Medicine, University of Hong Kong, Hong Kong
    • ,
  • Y Zhang

      Affiliations

    • Chongqing University of Medical Science, Chongqing 400046, People's Republic of China
    • ,
  • X.S Liu

      Affiliations

    • Chongqing University of Medical Science, Chongqing 400046, People's Republic of China
    • ,
  • X.R Xu

      Affiliations

    • Chongqing University of Medical Science, Chongqing 400046, People's Republic of China
    • ,
  • B.Z Liu

      Affiliations

    • Chongqing University of Medical Science, Chongqing 400046, People's Republic of China
    • ,
  • Y.J He

      Affiliations

    • Chongqing University of Medical Science, Chongqing 400046, People's Republic of China

Received 7 September 1999 ,Accepted 24 October 2000.

References 

  1. Huang M-E, Ye Y-C, Chen S-R, et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567–572
  2. Zhang Y, Jiang JK, Qing JP, et al. Induced differentiation of human erythro-leukemia K562 by Matrine. In: Third Asia International Cancer Congress (Abstracts), 1996, p. 79.
  3. Sharma HW, Sokoloski JA, Perez JR, et al.  Differentiation of immortal cells inhibits telomerase activity. Proc. Natl. Sci. Acad. USA. 1995;92:12343–12346
  4. Counter CM, Gupta J, Harley CB, et al.  Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 1995;85:2315–2320
  5. Zhu X, Kumar R, Mandal M, et al.  Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA. 1996;93:6091–6095
  6. Han R. Research and development of anticancer drugs and experimental techniques. 1996;48.
  7. Tabilio A, Pelicci PG, Vinci G, et al.  Myeloid and megakaryocytic properties of K562 cell lines. Cancer Res. 1983;43:4569–4574
  8. Bestilny LJ, Brown CB, Miura Y, et al.  Selective inhibition of telomerase during terminal differentiation of immortal cell lines. Cancer Res. 1996;56:3796–3802
  9. Keyomarsi K, Sandoval L, Band V, et al.  Synchronization of tumor and normal cells from G1 to multiple cell cycles by Lovastatin. Cancer Res. 1996;51:3602–3609
  10. Meichle A, Mantner J, Albert T, et al.  The functions of myc proteins. Biochimica et Biophysica. 1992;1114:129–146
  11. Pullner A, Mantner J, Albert T, et al. Nucleosomal structure of active and inactive c-myc genes. J. Bio. Chem. 271:31452–7.
  12. Filmus J, Buick R. Relationship of c-myc expression to differentiation and proliferation of HL-60 cells. Cancer Res. 1985;45:822
  13. Jenkinson D, Rutherford TR, Gordon Smith TC. Activated N-ras causes differentiation of K562 cells. Biochem. Soc. Trans. 1997;25:252
  14. Chang F, Syrjanen S, Kurvinen K. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Ann. J. Gastroenterol. 1993;88:174–177
  15. D.P. Lane (1993) p53, Guardian of the genome. Nature; 358, 15–17
  16. Reid BJ, Sanchez CA, Blount PL. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology. 1993;105:119–129

PII: S0145-2126(00)00145-4

Leukemia Research
Volume 25, Issue 9 , Pages 793-800 , 1 September 2001

Article Tools

* Image Usage & Resolution